Navigation Links
Mayo Clinic: Raoul Tibes, M.D., Ph.D., to receive Career Development Award
Date:6/3/2011

CHICAGO -- Rauol Tibes, M.D., Ph.D., the associate director of the Acute and Chronic Leukemias Program at Mayo Clinic in Arizona, will receive a Career Development Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology (formerly known as the ASCO Cancer Foundation) at the annual ASCO meeting this weekend in Chicago.

VIDEO ALERT: Additional audio and video resources are available at the Mayo Clinic News Blog.

Dr. Tibes is one of only eight researchers in the United States selected to receive the Conquer Cancer Foundation of ASCO Career Development Award this year. The award, a three year grant totaling $200,000, will help fund the next phase of Mayo Clinic's translational research in acute myeloid leukemia (AML) led by Dr. Tibes and his team of colleagues.

The Career Development Awards are presented to physicians who are within their first to third year of full-time, primary faculty appointment in a clinical department at an academic medical institution.

"I am very happy and proud," said Dr. Tibes, upon learning that his research effort from his laboratory, designed to advance new therapies for patients with acute leukemias, was recognized with this honor.

The crux of this translational research focuses on how to make the drug Cytarabine (one of the most actively used drugs administered to leukemia patients), more potent and effective, particularly for leukemia patients who have failed prior therapies and whose leukemia has relapsed.

Dr. Tibes said this kind of translational research project was greatly accelerated when he and his team began adapting RNA interference (RNAi) to leukemia research.

"We performed a large scale RNAi screening knocking down (or inhibiting) 572 kinases (genes that drive growth)," explained Dr. Tibes. "As a result, when the WEE1 kinase was inhibited, a more potent effect of Cytarabine was produced."

"This technology allowed us to select the gene, out of hundreds to thousands of genes, that most strongly enhances the activity of Cytarabine. This is a tremendous selection to pick the "winner" gene that can then be targeted with new drugs together with Cytarabine," said Dr. Tibes, who, along with his laboratory team, is performing similar RNAi screens for other commonly used cancer drugs with the goal of accelerating the design of new therapies for Mayo Clinic.

Dr. Tibes said the proposed next step is to take the positive findings of the Cytarabine combination with the WEE1 kinase inhibitor he has seen in the laboratory setting and translate it to a clinical trial to see if it is a more effective therapy for patients with advanced, acute and chronic leukemias.

"One of our goals at Mayo Clinic is to improve patient care through translational research," said Keith Stewart, M.B.Ch.B., dean of research at Mayo Clinic in Arizona. "It is our hope this research may offer leukemia patients a treatment alternative when standard therapies fail," Dr. Stewart added.

"One of the big challenges, especially for acute leukemias, is that therapies haven't changed in decades. The treatment of acute leukemias, specifically AML has lagged behind. We aim to find new therapeutic combinations for patients with this research," said Ruben Mesa, M.D., chair, Division of Hematology and Medical Oncology at Mayo Clinic in Arizona.


'/>"/>

Contact: Julie Janovsky-Mason
newsbureau@mayo.edu
480-301-4222
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Atlanta School of Massage Celebrates 30th Anniversary with a New Green Design and New Name for its Teaching Clinic: SensAbility
2. AMA Honors Vice Admiral John Mateczun, M.D., With Top Government Service Award
3. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
4. University of Utah afib specialist, Marcos Daccarett, M.D., wins Young Investigator Award
5. Joan Miller, M.D., receives 2010 Leadership Award for the Advancement of Women Faculty
6. Gino Tutera, M.D., F.A.C.O.G. Brings SottoPelle Therapy to Middle Tennessee, Opens Practice in Nashville Medical District
7. Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World
8. Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study
9. O. Marion Burton, M.D., F.A.A.P., addresses American Academy of Pediatrics in new term as president
10. Douglas A. Jabs, M.D., honored with Jackson Memorial Lecture by the American Academy of Ophthalmology
11. Donald M. Lloyd-Jones, M.D., recipient of the American Heart Associations 2010 Chairmans Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... NCPDP announced ... on Tuesday with Frank Luntz, sharing a dynamic, bi-partisan environmental scan of healthcare-related ... dive on NCPDP’s model solution to help stem the tide of the opioid ...
(Date:5/4/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – is set to return to the esteemed Quaker Ridge Golf Club in ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... The ... Day to recognize chaplains for their valuable support to patients and their families, and ... May 10. , To mark Spiritual Care Day, SCA has sent “Thank You Chaplain” ...
(Date:5/4/2016)... Charles, LA (PRWEB) , ... May 04, 2016 , ... ... Charles, LA area has teamed up with Big Brothers Big Sisters of Southwest Louisiana ... now being accepted here . , Big Brothers Big Sisters of Southwest Louisiana ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... SS&A teamed up with one of the top website design companies to create ... informative legal articles related to the law firm's main practice areas. These practice ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 BiondVax Pharmaceuticals Ltd. ... Ron Babecoff , will be attending the Joseph Gunnar ... . On Thursday, May 5, Dr. Babecoff will ... by Joseph Gunner & Co, taking place at ... that Dr. Babecoff will be using is downloadable from BiondVax,s ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
(Date:5/4/2016)... Research and Markets has ... Keratosis Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... Highlights 2016, provides comprehensive insights into Actinic ... Keratosis market valuations and forecast, Actinic Keratosis ...
Breaking Medicine Technology: